ACROBiosystems PMDA Certificate No. 47 for IL-15 Streamlines Japan Cell & Gene Therapy Trials

For cell and gene therapy developers targeting the Japanese market, raw material quality and regulatory acceptance are critical hurdles. ACROBiosystems' newly obtained PMDA Material Suitability Confirmation for its GMP-grade IL-15 offers a pre-vetted solution, potentially cutting months off clinical trial preparation and increasing confidence in supply chain compliance.

In July 2026, ACROBiosystems, a supplier of recombinant proteins and critical raw materials for the biopharmaceutical industry, announced it had received a Material Suitability Confirmation from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its GMP-grade Human IL-15 protein. This confirmation, certificate number 薬機審長発第47号, is part of an official PMDA evaluation system designed to pre-approve key raw materials used in the manufacture of regenerative medicine products such as CAR-T, CAR-NK, and TCR-T cell therapies. The system allows developers to obtain early regulatory assurance that their chosen raw materials meet safety and compliance standards, significantly reducing the documentation and review burden during subsequent clinical trial and marketing approval applications.

“

ACROBiosystems' newly obtained PMDA Material Suitability Confirmation for its GMP-grade IL-15 offers a pre-vetted solution, potentially cutting months off clinical trial preparation and increasing confidence in supply chain compliance.

The PMDA’s Material Suitability Confirmation is not a product approval per se, but it serves as a powerful endorsement of a supplier’s quality management system, traceability, and the absence of risky components. According to ACROBiosystems, to achieve this confirmation, the IL-15 product had to satisfy stringent criteria: it must not contain human or animal-derived components that require additional compliance proof under biological raw material guidelines, or if present, provide sufficient evidence; it must not include physiologically active substances, toxic elements, or heavy metals that could directly compromise patient safety; and the entire manufacturing process must operate under a robust quality system with full supply chain traceability and validated testing data. The confirmation explicitly states that ACROBiosystems’ IL-15 meets these requirements and that no animal or human-derived components requiring further proof are used in its preparation.

For cell and gene therapy developers targeting the Japanese market, this confirmation is strategically significant. IL-15 is a key cytokine used extensively in the manufacturing of CAR-T and NK cell therapies to promote cell expansion and persistence. Using a PMDA-confirmed GMP-grade raw material can streamline the regulatory filing process, as the agency has already reviewed and accepted the material’s safety profile. This can translate into faster clinical trial application approvals and a smoother path to market. Given the complexity of regenerative medicine regulations in Japan—which include the Act on the Safety of Regenerative Medicine and the Pharmaceutical and Medical Device Act—any pre-cleared component reduces risk and accelerates timelines.

The announcement also signals ACROBiosystems’ deepening engagement with the Japanese biopharma ecosystem. The company has positioned itself as a provider of high-quality, research- and GMP-grade proteins, and this official confirmation from a major regulatory body burnishes its reputation as a trusted partner. It may encourage other CGT developers to source IL-15 and potentially other raw materials from ACROBiosystems, leveraging the existing regulatory acceptance. Japan has been a pioneer in regenerative medicine, with early approvals of induced pluripotent stem cell (iPSC) and CAR-T therapies. As more allogeneic and autologous cell therapies enter clinical trials, demand for certified raw materials will likely increase. ACROBiosystems’ move preempts this demand, giving it a competitive edge.